The TRAIL to selective tumor death, Nat. Med, vol.5, pp.146-147, 1999. ,
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat. Med, vol.5, pp.157-163, 1999. ,
Death receptors as targets in cancer, Br. J. Pharmacol, vol.169, pp.1723-1744, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00823459
Antibodies and derivatives targeting DR4 and DR5 for cancer therapy, Antibodies, vol.6, p.16, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01626582
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study, Cancer Chemother. Pharmacol, vol.79, pp.1141-1149, 2017. ,
Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma, Chin. J. Cancer, vol.35, p.86, 2016. ,
Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L, Cell Death Differ, vol.14, pp.2021-2034, 2007. ,
Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity, Cancer Res, vol.70, pp.1101-1110, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00451170
Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing, Nano. Lett, vol.15, pp.891-895, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01113419
TRAIL receptor-2 signals apoptosis through FADD and caspase-8, Nat. Cell Biol, vol.2, pp.241-243, 2000. ,
An induced proximity model for caspase-8 activation, J. Biol. Chem, vol.273, pp.2926-2930, 1998. ,
TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress, Oncotarget, vol.8, pp.9974-9985, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01423110
Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity, Cancer Cell, vol.26, pp.177-189, 2014. ,
TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo, Oncoimmunology, vol.5, p.1131380, 2016. ,
Therapeutic antibodies: current state and future trends-is a paradigm change coming soon?, Methods Mol. Biol, vol.525, pp.1-27, 2009. ,
Mining naive rabbit antibody repertoires by phage display for monoclonal antibodies of therapeutic utility, J. Mol. Biol, vol.429, pp.2954-2973, 2017. ,
Therapeutic antibodies by phage display, Curr. Pharm. Des, vol.22, pp.6538-6559, 2016. ,
DNA versus protein immunisation for production of monoclonal antibodies against Choristoneura fumiferana ecdysone receptor (CfEcR), Vaccine, vol.24, pp.3115-3126, 2006. ,
The REFOLD database: a tool for the optimization of protein expression and refolding, Nucleic Acids Res, vol.34, pp.207-212, 2006. ,
Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunization, Hum. Vaccin. Immunother, vol.9, pp.2157-2164, 2013. ,
Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs, Nature, vol.352, pp.815-818, 1991. ,
Site-specific gene expression in vivo by direct gene transfer into the arterial wall, Science, vol.249, pp.1285-1288, 1990. ,
Heterologous protection against influenza by injection of DNA encoding a viral protein, Science, vol.259, pp.1745-1749, 1993. ,
Genetic immunization is a simple method for eliciting an immune response, Nature, vol.356, pp.152-154, 1992. ,
A rapid and simple approach to preparation of monoclonal antibody based on DNA immunization, Cell Mol. Immunol, vol.1, pp.295-299, 2004. ,
Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins, Methods Enzymol, vol.322, pp.325-345, 2000. ,
TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT, PLoS ONE, vol.6, p.19679, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00590415
Efficient selection for high-expression transfectants with a novel eukaryotic vector, Gene, vol.108, pp.193-199, 1991. ,
N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death, Cell Death Differ, vol.24, pp.500-510, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01467849
Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells, Int. J. Cancer, vol.50, pp.677-682, 1992. ,
Antibodies to major histocompatibility antigens produced by hybrid cell lines, Nature, vol.266, pp.550-552, 1977. ,
An improved and robust DNA immunization method to develop antibodies against extracellular loops of multi-transmembrane proteins, MAbs, vol.6, pp.95-107, 2014. ,
p53-mediated upregulation of DcR1 impairs oxaliplatin/ TRAIL-induced synergistic anti-tumour potential in colon cancer cells, Oncogene, vol.27, pp.4161-4171, 2008. ,
Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion, Cell Death Dis, vol.6, p.1633, 2015. ,
Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level, Cell Death Differ, vol.18, pp.700-711, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00525443
A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes, Mol. Cancer Ther, vol.8, pp.2276-2285, 2009. ,
Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2, Clin. Cancer Res, vol.11, pp.3126-3135, 2005. ,
Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase8 predictive of response, Clin. Cancer Res, vol.17, pp.3181-3192, 2011. ,
Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA, Int. J. Cancer, vol.131, pp.2562-2572, 2012. ,
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction, MAbs, vol.6, pp.1560-1570, 2014. ,
Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo, Neuro Oncol, vol.12, pp.687-700, 2010. ,
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib, Mol. Cancer Ther, vol.8, pp.292-302, 2009. ,
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells, Oncogene, vol.34, pp.2138-2144, 2015. ,
Fully human monoclonal antibodies to TRAIL-R1 enhance TRAILinduced apoptosis via activation of caspase-8 pathway, Biochem. Biophys. Res. Commun, vol.475, pp.238-244, 2016. ,
Identification of novel epitopes with agonistic activity for the development of tumor immunotherapy targeting TRAIL-R1, J. Cancer, vol.8, pp.2542-2553, 2017. ,
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer, J. Mol. Med, vol.87, pp.995-1007, 2009. ,
Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer, Clin. Cancer Res, vol.15, pp.650-659, 2009. ,
Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/ DR5) expression in acute myelogenous leukemia, Leuk. Res, vol.28, pp.359-365, 2004. ,
Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations, Mol. Cancer, vol.9, p.203, 2010. ,
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL), J. Clin. Oncol, vol.26, pp.3621-3630, 2008. ,
Principles of antibody-mediated TNF receptor activation, Cell Death Differ, vol.22, pp.1727-1741, 2015. ,
Safety and antitumor activity of recombinant soluble Apo2 ligand, J. Clin. Invest, vol.104, pp.155-162, 1999. ,
Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types, Cancer Biol. Ther, vol.9, pp.618-631, 2010. ,
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy, J. Exp. Med, vol.199, pp.437-448, 2004. ,